Cytomegalovirus vaccine strategies

Bibliography

• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17:335-63
   Google Scholar
• Whitley RJ. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 2004;549:155-60
   PubMed Web of Science ®Google Scholar
• Ross DS, Dollard SC, Victor M, et al. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health 2006;15:224-9
   PubMed Web of Science ®Google Scholar
• Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. J Am Med Assoc 1986;256:1904-8
   PubMed Web of Science ®Google Scholar
• Nance WE, Lim BG, Dodson KM. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J Clin Virol 2006;35:221-5
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Sanchez PJ, et al. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fast P, Myers M, et al. National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004;39:233-9
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decisionmaking. Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC; 1999
   Google Scholar
• Mocarski ES, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, editors, Field's virology. Lippincott–Raven, New York; 2001. p. 2629-73
   Google Scholar
• Varnum SM, Streblow DN, Monroe ME, et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 2004;78:10960-6
   PubMed Web of Science ®Google Scholar
• Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85
   PubMed Web of Science ®Google Scholar
• Marshall GS, Stout GG, Knights ME, et al. Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol 1994;43:77-83
   PubMed Web of Science ®Google Scholar
• Kari B, Gehrz R. Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II. Arch Virol 1990;114:213-28
   PubMed Web of Science ®Google Scholar
• Mach M, Kropff B, Kryzaniak M, Britt W. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 2005;79:2160-70
   PubMed Web of Science ®Google Scholar
• Urban M, Klein M, Britt WJ, et al. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996;77:1537-47
   PubMed Web of Science ®Google Scholar
• Shimamura M, Mach M, Britt WJ. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 2006;80:4591-600
   PubMedGoogle Scholar
• McLaughlin-Taylor E, Pande H, Forman SJ, et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 1994;43:103-10
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79
   PubMed Web of Science ®Google Scholar
• Lacey SF, Gallez-Hawkins G, Crooks M, et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002;74:722-32
   PubMedGoogle Scholar
• Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002;185:1709-16
   PubMed Web of Science ®Google Scholar
• Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000;181:1537-46
   PubMed Web of Science ®Google Scholar
• Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004;172:2256-64
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Lacey SF, et al. Characterization of host immunity to cytomegalovirus pp150 (UL32). Hum Immunol 2005;66:116-26
   PubMedGoogle Scholar
• Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673-85
   PubMed Web of Science ®Google Scholar
• Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 1986;314:1414-8
   PubMed Web of Science ®Google Scholar
• Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001;19:1356-62
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006;259:219-46
   PubMed Web of Science ®Google Scholar
• Zanghellini F, Boppana SB, Emery VC, et al. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999;180:702-7
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev. Vaccines 2005;4:381-406
   Google Scholar
• Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171:26-32
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B, et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006;24:5311-9
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006;193:1350-60
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002;21:133-8
   PubMed Web of Science ®Google Scholar
• Pass R, Zhang C, Simpson T, et al. Cytomegalovirus (CMV) envelope glycoprotein B (gB) vaccine in young women. Abstracts of the 45th Annual Infectious Diseases Society of America (IDSA) meeting 2007, San Diego, California, USA. Late breaker abstract #8. Available from: http://idsociety.org/PrintFriendly.aspx?id=7048 [Last accessed 17 March 2008]
   Google Scholar
• Selinsky C, Luke C, Wloch M, et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005;1:16-23
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002;185:686-90
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001;183:1171-9
   PubMed Web of Science ®Google Scholar
• Wang Z, Rosa CL, Li Z, et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 2007;25:1132-41
   PubMed Web of Science ®Google Scholar
• Reap EA, Morris J, Dryga SA, et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 2007;25:7441-9
   PubMedGoogle Scholar
• Schleiss MR, Lacayo J, Belkaid Y, et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007;195:789-98
   PubMed Web of Science ®Google Scholar
• Morello CS, Kelley LA, Munks MW, et al. DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge. J Virol 2007;81:7766-75
   PubMed Web of Science ®Google Scholar
• Pepperl S, Munster J, Mach M, et al. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol 2000;74:6132-46
   PubMed Web of Science ®Google Scholar
• Benmohamed L, Krishnan R, Longmate J, et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum Immunol 2000;61:764-79
   PubMed Web of Science ®Google Scholar
• Rist M, Cooper L, Elkington R, et al. Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur J Immunol 2005;35:996-1007
   PubMed Web of Science ®Google Scholar
• Cicin-Sain L, Brune W, Bubic I, et al. Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol 2003;77:8249-55
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Stroup G, Pogorzelski K, McGregor A. Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. Vaccine 2006;24:6175-86
   PubMed Web of Science ®Google Scholar
• Cicin-Sain L, Bubic I, Schnee M, et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol 2007;81:13825-34
   PubMedGoogle Scholar
• Garcia-Ramirez JJ, Ruchti F, Huang H, et al. Dominance of virus over host factors in cross-species activation of human cytomegalovirus early gene expression. J Virol 2001;75:26-35
   PubMedGoogle Scholar